PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

46,012 stories, page 678 of 767

Advanced search
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Development of phenotype algorithms for the detection of adverse events in electronic health record data: a multicentre study.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

First-in-human (phase I) trial of SOL-116, a humanised IgG4 monoclonal antibody targeting bile salt-stimulated lipase, in healthy participants and rheumatoid arthritis patients.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Patient Perceptions on the Use of Artificial Intelligence in Creating Clinical Research Documents: Survey Study.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Carob pod aqueous extract potentiates cisplatin efficacy and reduces toxicity in experimental hepatocellular carcinoma via mitochondrial and inflammatory pathway modulation.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Language as an Eligibility Criterion in Pediatric Study Protocols Conducted in Europe (2007-2024) Reported in the ClinicalTrials.gov Database.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

A Framework for Standardising Toxicity Management Guidelines in Oncology Clinical Trials.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Clinical translation and landscape of stimuli-responsive nanomedicines and microscale therapeutics.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials.

Europe PMCOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT07661940: Efficacy and Safety of SP16 in Preventing Acute Kidney Injury in At-risk Subjects With Chronic Kidney Disease Undergoing Elective Cardiac Surgery Using the Heart-lung-machine

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT07661797: Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT07661368: Cooking Health-Oriented Meals to Prevent Dementia and Diabetes

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT07660978: Cognitive-Based Balance Rehabilitation in Parkinson's Disease: Virtual Reality vs. Dual Task

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT07660289: Combined Advanced Targeted Therapy for Inflammatory Bowel Disease

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT07658950: Efficacy of INTOFINE-JOINT SUPPORT DIETARY SUPPLEMENT on Bone and Joint Health

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT07379138: Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT07339046: [Trial of device that is not approved or cleared by the U.S. FDA]

Study type: . Phase: .

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT07318558: A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Study type: INTERVENTIONAL. Phase: PHASE3.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT06853314: An Effectiveness Trial of the PrEP for WINGS Study

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT06833762: Clinical and CPET Parameters That Predict Improvement in Functional Capacity After TAVI

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT06698640: A Trial of AI-Powered Text Message Outreach on Well-Child Visit Completion

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT06690255: Trial of an Online Spanish Pivotal Response Treatment Training in Autism Spectrum Disorder

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT06591845: Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT05970172: A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Study type: INTERVENTIONAL. Phase: PHASE3.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT03097939: Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT01168271: Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA Advisory No.2026-0622 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “Pepslim Bacteriostatic Water 3mL Vial” - Food and Drug Administration

fda.gov.phOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

MoonLake reports phase 3 hidradenitis suppurativa trial results

Investing.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

MoonLake Announces Week 52 Results of Sonelokimab from its

GlobeNewswireOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Definium sets webcast on Phase 3 depression study results for June 22

Stock TitanOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA’s drug repurposing initiative signals renewed focus

Drug Discovery NewsOriginal source
🌍Medialemsurgical.comTier 2 · Direct publisher

Built Different: The Case for Specialized Humanoids

LEM Surgical (Dynamis Spine Robot)Original source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: OCSINL WART REMOVER

Official structured record identifier: 54c206b9-758e-4baf-e063-6394a90afa99.

openFDA Drug LabelsOriginal source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: Oneoo Nicotine Gum (Mint)

Official structured record identifier: 54b1329b-b422-29a5-e063-6294a90a8780.

openFDA Drug LabelsOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

A patient-centered conceptual model and measurement framework for migraine experience developed by the Migraine Clinical Outcome Assessment System.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook.

Europe PMCOriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Longitudinal Examination of Neighborhood Disadvantage, Cognitive Aging, and Alzheimer's Disease Risk in Disinvested, African American Neighborhoods

Recipient: UNIVERSITY OF PITTSBURGH AT PITTSBURGH. Award amount: 1540838.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: The Impact of a Race-Based Stress Reduction Intervention on Well-Being, Inflammation, and DNA methylation in Older African American Women at Risk for Cardiometabolic Disease

Recipient: LOYOLA UNIVERSITY CHICAGO. Award amount: 651710.

NIH RePORTEROriginal source
🇺🇸Researchreporter.nih.govTier 2 · Direct publisher

NIH award: Predictors of Altered CNS Structure, Function, and Connectomics in the Elderly using a Health Disparities Framework

Recipient: UNIVERSITY OF PITTSBURGH AT PITTSBURGH. Award amount: 2274144.

NIH RePORTEROriginal source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: Atenolol

Official structured record identifier: 7f8304a4-93de-774f-e053-2a91aa0aa5b5.

openFDA Drug LabelsOriginal source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: Subleef SKIN WART CORN REMOVER

Official structured record identifier: 54aeb166-d703-1d23-e063-6394a90a19a4.

openFDA Drug LabelsOriginal source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: Tizanidine

Official structured record identifier: 54ade0c7-4bf0-54d4-e063-6294a90a8b17.

openFDA Drug LabelsOriginal source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: Olanzapine

Official structured record identifier: 54adae9e-6781-6a77-e063-6394a90ab5c8.

openFDA Drug LabelsOriginal source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: Toothache

Official structured record identifier: 54ad2ceb-272f-e5ba-e063-6394a90aec5f.

openFDA Drug LabelsOriginal source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: BABIES KIDSSUN PROTECTION

Official structured record identifier: 3a554118-b71d-a844-e063-6294a90a699f.

openFDA Drug LabelsOriginal source
🇺🇸Regulatoryopen.fda.govTier 1 · Regulatory source

Drug label update: unspecified product

Official structured record identifier: 046465b7-ebad-4e57-838d-bbf8f7b7802d.

openFDA Drug LabelsOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Clinical Trial and Ontology-Derived Positive and Negative Benchmark Datasets for Drug Repurposing Across Rare Diseases

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

A conceptual matrix model of patient involvement and patient expertise in medicines and medical technology research and development.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Evolving landscape of drug development for pediatric rare diseases-from successes to strategies for addressing unmet needs.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Clinical efficacy of Danggui Sini Decoction for treatment of lower limb arteriosclerosis obliterans: A randomized controlled trial.

Europe PMCOriginal source
🇮🇹Industryrecordati.comTier 1 · Company source

On behalf of Respighi BidCo S.p.A – Press Release pursuant to Article 38, paragraph 1, of the Issuers’ Regulation – Suspension of the review period

RecordatiOriginal source
🇺🇰Regulatorygov.ukTier 1 · Regulatory source

Resident doctors to vote on government offer to end strikes

Resident doctors will vote on an offer that will see greater opportunities for career progression, b...

UK Department of Health and Social CareOriginal source
🇺🇰Regulatorygov.ukTier 1 · Regulatory source

Joint Statement on Asbestos in Consumer Products

Joint Statement from OPSS, UKHSA and HSE.

UK Health Security AgencyOriginal source
🇺🇰Regulatorygov.ukTier 1 · Regulatory source

Brucella serology referral form

Form (Y3) for laboratory diagnosis of Brucella by the Brucella Reference Unit (BRU) using serology t...

UK Health Security AgencyOriginal source
🌍Regulatorywho.intTier 1 · Regulatory source

Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo & Uganda

WHO Disease Outbreak NewsOriginal source
🇺🇰Regulatorygov.ukTier 1 · Regulatory source

The Primary Dental Services Statement of Financial Entitlements (Amendment) (No.3) Directions 2026

Makes changes to the payments made by NHS England to contractors under dental service contracts with...

UK Department of Health and Social CareOriginal source
🇩🇪Researchuk-essen.deTier 2 · Direct publisher

Universitätsklinikum Essen besteht TÜV-Überwachungsaudit nach ISO 9001 erneut erfolgreich

Universitätsklinikum EssenOriginal source
🇺🇰Regulatorygov.ukTier 1 · Regulatory source

Birmingham public health laboratory: user handbook

The UKHSA public health laboratory in Birmingham provides a range of public health microbiology serv...

UK Health Security AgencyOriginal source
🇩🇪Mediadzne.deTier 2 · Direct publisher

25,000 Genomes for Brain Health

DZNE (Neurodegenerative Diseases)Original source